OpenLB
Open Library of Bioscience
Advanced Search
Clinical journal of gastroenterology
Feb, 2024;17 (1): 188-197.

A case of pseudomyxoma peritonei arising from a perforated intraductal papillary mucinous neoplasm that underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Yuhi Yoshizaki, Yoshimasa Gohda, Fuyuki Inagaki, Atsuko Kataoka, Nobuyuki Takemura, Hideki Miyazaki, Toru Igari, Tomomichi Kiyomatsu, Hideaki Yano, Norihiro Kokudo
Author Information
  1. Yuhi Yoshizaki: Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
  2. Yoshimasa Gohda: Department of Surgery, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan. ygohda@hosp.ncgm.go.jp. ORCID
  3. Fuyuki Inagaki: Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
  4. Atsuko Kataoka: Department of Surgery, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
  5. Nobuyuki Takemura: Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
  6. Hideki Miyazaki: Department of Pathology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
  7. Toru Igari: Department of Pathology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
  8. Tomomichi Kiyomatsu: Department of Surgery, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
  9. Hideaki Yano: Department of Surgery, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
  10. Norihiro Kokudo: Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
PMID: 37980306 DOI: 10.1007/s12328-023-01890-y

Abstract

Pseudomyxoma peritonei (PMP) of pancreatic origin arising from an intraductal papillary mucinous neoplasm (IPMN) is rare. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has been established as the optimal treatment for PMP. However, the benefits and safety of CRS with HIPEC for treating PMP of pancreatic origin remain unclear. Herein, we describe a case of PMP of pancreatic origin that was treated with CRS and HIPEC without postoperative complications. A 75-year-old woman was referred to our department. Computed tomography (CT) revealed a multilocular cystic tumor in the pancreatic tail, notable mucinous ascites in the abdominal cavity, and scalloping of the liver and spleen. CT did not reveal the appendix, and the ovaries were normal in size. The patient was diagnosed with PMP of pancreatic origin, and CRS and HIPEC were performed. Intraoperatively, the pancreatic tumor was perforated, and there was a large amount of mucinous ascites. We performed distal pancreatectomy in addition to CRS and HIPEC, with no intraoperative complications. The postoperative course was uneventful, and the patient survived after 6 months without recurrence. CRS with HIPEC may be a feasible treatment option for PMP of pancreatic origin.

Keywords

Cytoreductive surgery Hyperthermic intraperitoneal chemotherapy Intraductal papillary mucinous neoplasm Pancreas Pseudomyxoma peritonei

References

  1. Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219:112–9. [PMID: 8129481]
  2. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76. [PMID: 16389186]
  3. Moran BJ, Cecil TD. The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am. 2003;12:585–603. [PMID: 14567019]
  4. Kataoka A, Ito K, Takemura N, et al. Immunohistochemical staining as supportive diagnostic tool for pseudomyxoma peritonei arising from intraductal papillary mucinous neoplasm: a report of two cases and literature review. Pancreatology. 2020;20:1226–33. [PMID: 32768178]
  5. Ansari N, Chandrakumaran K, Dayal S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol. 2016;42:1035–41. [PMID: 27132072]
  6. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56. [PMID: 22614976]
  7. Fung X, Li IC, Chandrakumaran K, et al. Early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in 632 patients with pseudomyxoma peritonei of appendiceal origin: a single institution experience. Eur J Surg Oncol. 2022;48:1614–8. [PMID: 35168851]
  8. Youssef H, Newman C, Chandrakumaran K, et al. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum. 2011;54:293–9. [PMID: 21304299]
  9. Sugarbaker PH. Technical handbook for the integration of cytoreductive surgery and perioperative intraperitoneal chemotherapy into the surgical managements of gastrointestinal and gynecologic malignancy. 4th ed. Michigan: The Ludann Company Grand Rapids; 2005.
  10. Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment. Int J Hyperth. 2017;33:511–9.
  11. Smeenk RM, van Velthuysen ML, Verwaal VJ, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34:196–201. [PMID: 17524597]
  12. Han XD, Zhou N, Lu YY, et al. Pseudomyxoma peritonei originating from intestinal duplication: a case report and review of the literature. World J Clin Cases. 2021;9:7459–67. [PMID: 34616812]
  13. Zanelli M, Casadei R, Santini D, et al. Pseudomyxoma peritonei associated with intraductal papillary-mucinous neoplasm of the pancreas. Pancreas. 1998;17:100–2. [PMID: 9667528]
  14. Jabłońska B. Pancreatic cysts: etiology, diagnosis and management. Cent Eur J Med. 2014;9:92–107.
  15. Jabłońska B, Szmigiel P, Mrowiec S. Pancreatic intraductal papillary mucinous neoplasms: current diagnosis and management. World J Gastrointest Oncol. 2021;13:1880–95. [PMID: 35070031]
  16. Hirono S, Yamaue H. Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas. Surg Today. 2020;50:50–5. [PMID: 31807871]
  17. Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of International Consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17:738–53. [PMID: 28735806]
  18. Furukawa T, Kloppel G, Volkan Adsay N, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005;447:794–9. [PMID: 16088402]
  19. Imaoka H, Yamao K, Hijioka S, et al. Pseudomyxoma peritonei arising from intraductal papillary neoplasm after surgical pancreatectomy: report of 2 cases and review of the literature. Clin J Gastroenterol. 2012;5:15–9. [PMID: 26181869]
  20. Sirisai C, Yonemura Y, Ishibashi H, et al. Hyperthermic intraperitoneal chemotherapy in management of malignant intraductal papillary mucinous neoplasm with peritoneal dissemination: case report. Int J Surg Case Rep. 2019;63:85–8. [PMID: 31574455]
  21. Imaoka H, Yamao K, Salem AA, et al. Pseudomyxoma peritonei caused by acute pancreatitis in intraductal papillary mucinous carcinoma of the pancreas. Pancreas. 2006;32:223–4. [PMID: 16552347]
  22. Adsay NV, Merati K, Basturk O, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an “intestinal” pathway of carcinogenesis in the pancreas. Am J Surg Pathol. 2004;28:839–48. [PMID: 15223952]
  23. Basturk O, Khayyata S, Klimstra DS, et al. Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis. Am J Surg Pathol. 2010;34:364–70. [PMID: 20139757]
  24. Delhorme JB, Severac F, Averous G, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin. Br J Surg. 2018;105:668–76. [PMID: 29412465]
  25. Furukawa T, Klöppel G, Volkan Adsay N, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005;447:794–9. [PMID: 16088402]
  26. Kloek JJ, van der Gaag NA, Erdogan D, et al. A comparative study of intraductal papillary neoplasia of the biliary tract and pancreas. Hum Pathol. 2011;42:824–32. [PMID: 21292296]
  27. Strickland S, Parra-Herran C. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours. Histopathology. 2016;68:977–87. [PMID: 26542609]
  28. Arjona-Sanchez A, Munoz-Casares C, Ortega-Salas R, et al. Long-term survival with peritoneal mucinous carcinomatosis from intraductal mucinous papillary pancreatic carcinoma treated with complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Int J Hyperth. 2014;30:408–11.
  29. Hackeng WM, de Guerre L, Kuypers KC, et al. Pseudomyxoma peritonei after a total pancreatectomy for intraductal papillary mucinous neoplasm with colloid carcinoma in lynch syndrome. Pancreas. 2019;48:135–8. [PMID: 30531244]
  30. Yajima N, Wada R, Yamagishi S, et al. Immunohistochemical expressions of cytokeratins, mucin core proteins, p53, and neuroendocrine cell markers in epithelial neoplasm of appendix. Hum Pathol. 2005;36:1217–25. [PMID: 16260276]
  31. Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture. Can J Surg. 1989;32:164–70. [PMID: 2713770]
  32. Rizvi SA, Syed W, Shergill R. Approach to pseudomyxoma peritonei. World J Gastrointest Surg. 2018;10:49–56. [PMID: 30190782]
  33. Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg. 1994;219:109–11. [PMID: 8129480]
  34. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74. [PMID: 8849962]
  35. Kim SI, Kim JW. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer. ESMO Open. 2021;6: 100149. [PMID: 33984680]
  36. Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156: e206363. [PMID: 33502455]
  37. de Bree E. Optimal drugs for HIPEC in different tumors. J Buon. 2015;20(Suppl 1):S40–6. [PMID: 26051331]
  38. Saint-Lorant G, Rodier S, Guilloit JM, et al. Is the blood of a surgeon performing HIPEC contaminated by irinotecan, its major metabolites and platinum compounds? Pleura Peritoneum. 2021;6:49–55. [PMID: 34179338]
  39. McConnell YJ, Mack LA, Francis WP, et al. HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol. 2013;107:591–6. [PMID: 23129533]
  40. Tan GH, Ong WS, Chia CS, et al. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference? Int J Hyperth. 2016;32:281–8.
  41. Rosenberger LH, Stein LH, Witkiewicz AK, et al. Intraductal papillary mucinous neoplasm (IPMN) with extra-pancreatic mucin: a case series and review of the literature. J Gastrointest Surg. 2012;16:762–70. [PMID: 22258877]
  42. Sugiura T, Kohga A, Uesaka K. Intraductal papillary mucinous neoplasm of the pancreas spontaneously ruptured into the peritoneal cavity. Jpn J Clin Oncol. 2015;45:998. [PMID: 26185137]
  43. Chua TC, Yan TD, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: A systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7. [PMID: 19474692]
  44. Sabol M, Donat R, Dyttert D, et al. Postoperative pancreatic fistula after pancreatic resection. Bratisl Lek Listy. 2020;121:541–6. [PMID: 32726115]
  45. Sullivan BJ, Leigh NL, Bekhor EY, et al. Distal pancreatectomy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: identifying risk and improving patient selection. Am J Surg. 2020;220:1235–41. [PMID: 32654767]
  46. Aronsson L, Marinko S, Ansari D, et al. Adjuvant therapy in invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a systematic review. Ann Transl Med. 2019;7:689. [PMID: 31930090]
  47. Hughes DL, Hughes I, Silva MA. Determining the role of adjuvant therapy in invasive intraductal papillary mucinous neoplasms: a systematic review and meta-analysis. Eur J Surg Oncol. 2022;48:1567–75. [PMID: 35144836]

MeSH Term

Female
Humans
Aged
Pseudomyxoma Peritonei
Hyperthermic Intraperitoneal Chemotherapy
Peritoneal Neoplasms
Ascites
Cytoreduction Surgical Procedures
Hyperthermia, Induced
Pancreatic Neoplasms
Retrospective Studies
Case Reports Journal Article

Word Cloud

Created with Highcharts 10.0.0pancreaticPMPCRSHIPECoriginmucinousperitoneipapillaryneoplasmsurgeryintraperitonealchemotherapyPseudomyxomaarisingintraductalCytoreductivehyperthermictreatmentcasewithoutpostoperativecomplicationsCTtumorascitespatientperformedperforatedIPMNrareestablishedoptimalHoweverbenefitssafetytreatingremainunclearHereindescribetreated75-year-oldwomanreferreddepartmentComputedtomographyrevealedmultilocularcystictailnotableabdominalcavityscallopingliverspleenrevealappendixovariesnormalsizediagnosedIntraoperativelylargeamountdistalpancreatectomyadditionintraoperativecourseuneventfulsurvived6 monthsrecurrencemayfeasibleoptionpseudomyxomaunderwentcytoreductiveHyperthermicIntraductalPancreas

Similar Articles

Cited By